Peptio

Sources

Every study, trial record and regulatory document cited anywhere on this site, listed with its study design and the species it was conducted in.

491 sources catalogued.

  1. Sheludchenko VM et al. [Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome]. Vestnik oftalmologii. 2026.

    case serieshumann = 42View source

  2. 21 CFR 201.128 Meaning of "intended uses". Electronic Code of Federal Regulations. 2026.

    guidancen aView source

  3. 21 CFR 809.10 Labeling for in vitro diagnostic products. Electronic Code of Federal Regulations. 2026.

    guidancen aView source

  4. A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery. ClinicalTrials.gov. 2026.

    case serieshumann = 40View source

  5. A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes). ClinicalTrials.gov. 2026.

    rcthumann = 4500View source

  6. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial (TRIUMPH-2). ClinicalTrials.gov. 2026.

    rcthumann = 1152View source

  7. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1). ClinicalTrials.gov. 2026.

    rcthumann = 2335View source

  8. A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye (ARISE-3). ClinicalTrials.gov. 2026.

    rcthumann = 700View source

  9. A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye: ARISE-2. ClinicalTrials.gov. 2026.

    rcthumann = 601View source

  10. A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus. ClinicalTrials.gov. 2026.

    rcthumann = 72View source

  11. A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus. ClinicalTrials.gov. 2026.

    rcthumann = 95View source

  12. A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of TB-500 (Thymosin Beta 4 17-23 Fragment) in Adults With Stable Atherosclerotic Cardiovascular Disease to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Cardiovascular Biomarkers. ClinicalTrials.gov. 2026.

    rcthumann = 80View source

  13. A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes. ClinicalTrials.gov. 2026.

    rcthumann = 281View source

  14. A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities. ClinicalTrials.gov. 2026.

    rcthumann = 338View source

  15. A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities. ClinicalTrials.gov. 2026.

    rcthumann = 300View source

  16. A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu (Copper(II)-Peptide Complex) Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults. ClinicalTrials.gov. 2026.

    rcthumann = 60View source

  17. A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c. ClinicalTrials.gov. 2026.

    rcthumanView source

  18. A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4). ClinicalTrials.gov. 2026.

    rcthumann = 445View source

  19. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity (TRIUMPH-5). ClinicalTrials.gov. 2026.

    rcthumann = 800View source

  20. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7). ClinicalTrials.gov. 2026.

    rcthumann = 586View source

  21. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (TRIUMPH-Outcomes). ClinicalTrials.gov. 2026.

    rcthumann = 10000View source

  22. A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1). ClinicalTrials.gov. 2026.

    rcthumann = 537View source

  23. A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3). ClinicalTrials.gov. 2026.

    rcthumann = 320View source

  24. A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2). ClinicalTrials.gov. 2026.

    rcthumann = 1250View source

  25. A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial (TRIUMPH-9). ClinicalTrials.gov. 2026.

    rcthumann = 600View source

  26. A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-8). ClinicalTrials.gov. 2026.

    rcthumann = 250View source

  27. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6). ClinicalTrials.gov. 2026.

    rcthumann = 643View source

  28. A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3). ClinicalTrials.gov. 2026.

    rcthumann = 1946View source

  29. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Melanotan II (Synthetic Cyclic Melanocortin Receptor Agonist) as an Adjunct to Narrowband UV-B Phototherapy in Adults With Stable Nonsegmental Vitiligo. ClinicalTrials.gov. 2026.

    rcthumanView source

  30. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain. ClinicalTrials.gov. 2026.

    rcthumann = 120View source

  31. A Randomized, Placebo-Controlled, Parallel Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia. ClinicalTrials.gov. 2026.

    rcthumann = 80View source

  32. A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3437943 in Healthy Subjects. ClinicalTrials.gov. 2026.

    rcthumann = 45View source

  33. A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO). ClinicalTrials.gov. 2026.

    guidancen aView source

  34. Badran AS et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.. Obesity Research & Clinical Practice. 2026.

    meta analysishumanView source

  35. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  36. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  37. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  38. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  39. Abulehia A et al. Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism. 2026.

    meta analysishumanView source

  40. Chen D et al. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. BMJ Medicine. 2026.

    meta analysishumann = 24214View source

  41. Piatkowski T et al. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Drug and Alcohol Review. 2026.

    in vitron an = 3View source

  42. Concerns regarding the public health risks associated with unapproved peptide products. Therapeutic Goods Administration. 2026.

    guidancen aView source

  43. Consumer advisory: Unapproved peptide products health warning. Medsafe (New Zealand Medicines and Medical Devices Safety Authority). 2026.

    guidancen aView source

  44. Laroche ML, Géniaux H, Jardou M. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. European Journal of Clinical Pharmacology. 2026.

    case serieshumanView source

  45. Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V. Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. High Blood Pressure & Cardiovascular Prevention. 2026.

    meta analysishumanView source

  46. Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. 2026.

    animalratn = 32View source

  47. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet. 2026.

    rcthumann = 537View source

  48. Ditta AM et al. Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.. Journal of the International Association of Providers of AIDS Care. 2026.

    meta analysishumann = 909View source

  49. Buzzi RM, Huber LC. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Reports. 2026.

    case reporthumann = 1View source

  50. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526). Federal Register. 2026.

    guidancen aView source

  51. FAERS adverse event reports for BPC-157, retrieved and summarised by FDA's Office of Surveillance and Epidemiology (database search through December 4, 2025), in the Pharmacy Compounding Advisory Committee briefing document. U.S. Food and Drug Administration. 2026.

    case reporthumann = 3View source

  52. FDA Briefing Document for Emideltide-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  53. FDA Briefing Document for Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate), Pharmacy Compounding Advisory Committee, July 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  54. FDA Briefing Document for MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate), Pharmacy Compounding Advisory Committee, July 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  55. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (Free Base) and BPC-157 Acetate) for Inclusion on the 503A Bulk Drug Substances List. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  56. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: Evaluation of TB-500-related Bulk Drug Substances (TB-500 (Free Base) and TB-500 acetate) for Inclusion on the 503A Bulk Drug Substances List. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  57. FDA Briefing Document: Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  58. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  59. FDA Global Substance Registration System, Melanotan II, UNII UPF5CJ93X7. U.S. Food and Drug Administration / NCATS GSRS. 2026.

    guidancen aView source

  60. FDA Global Substance Registration System, Retatrutide, UNII NOP2Y096GV. U.S. Food and Drug Administration, precisionFDA GSRS. 2026.

    guidancen aView source

  61. FDA Global Substance Registration System: DIHEXA (UNII 9WYX65A5C2). U.S. Food and Drug Administration / NCATS. 2026.

    in silicon aView source

  62. FDA Global Substance Registration System: EMIDELTIDE (UNII YN28Z5YZ73). U.S. Food and Drug Administration. 2026.

    guidancen aView source

  63. FDA Global Substance Registration System: EPITALON (UNII O65P17785G). U.S. Food and Drug Administration. 2026.

    guidancen aView source

  64. FDA Global Substance Registration System: MITOCHONDRIA-DERIVED PEPTIDE MOTS-C (UNII A5CV6JFB78). U.S. Food and Drug Administration / NCATS GSRS. 2026.

    in silicon aView source

  65. Steinzor P. FDA Panel Backs 6 Peptides for Compounding. AJMC (The American Journal of Managed Care). 2026.

    narrative reviewn aView source

  66. FDA Warning Letter, MARCS-CMS 718739, January 20, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  67. FDA Warning Letter, MARCS-CMS 721805, March 31, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  68. FDA Warning Letter, MARCS-CMS 721806, March 31, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  69. FDA Warning Letter, MARCS-CMS 733652, August 24, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  70. FDA Warning Letter, MARCS-CMS 734884, August 24, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  71. FDA Warning Letter, MARCS-CMS 735063, August 24, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  72. FDA Warning Letter, MARCS-CMS 735067, August 24, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  73. FDA Warning Letter, MARCS-CMS 735127, August 24, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  74. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (press announcement, March 3, 2026). U.S. Food and Drug Administration. 2026.

    guidancen aView source

  75. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  76. Vadner DJ, Smith S. Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use. JAAD Case Reports. 2026.

    case reporthumann = 1View source

  77. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. U.S. Department of Health and Human Services. 2026.

    guidancen aView source

  78. Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery. ClinicalTrials.gov. 2026.

    rcthumann = 30View source

  79. Import Alert 66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  80. Import Alert 66-80: Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances (published 09/21/2026). U.S. Food and Drug Administration. 2026.

    guidancen aView source

  81. Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94), EO 12866 regulatory review. Office of Information and Regulatory Affairs, Office of Management and Budget. 2026.

    guidancen aView source

  82. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  83. Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress (Form 8-K Exhibit 99.1). Eli Lilly and Company, filed with the U.S. Securities and Exchange Commission. 2026.

    press releasen aView source

  84. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. Eli Lilly and Company (press release, PR Newswire). 2026.

    press releasen aView source

  85. Medicines output: medicines report (generated 2 October 2026). European Medicines Agency. 2026.

    guidancen aView source

  86. Meeting of the Pharmacy Compounding Advisory Committee (to be scheduled before the end of February 2027). U.S. Food and Drug Administration. 2026.

    guidancen aView source

  87. Melanotan II tanning peptide products found to be inconsistently dosed. Therapeutic Goods Administration. 2026.

    guidancen aView source

  88. Mazzola J. Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. Research Square. 2026.

    animalmousen = 100View source

  89. MOUNJARO (tirzepatide) injection, for subcutaneous use. Prescribing Information, revised 08/2026 (NDA 215866, S-044 and S-045). U.S. Food and Drug Administration, Drugs@FDA. 2026.

    guidancen aView source

  90. Mounjaro: EPAR, Product Information (Annex I, Summary of Product Characteristics). European Medicines Agency. 2026.

    guidancen aView source

  91. NDA 215866/S-044 and S-045 supplement approval letter, Mounjaro (tirzepatide), major adverse cardiovascular events indication, August 27, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  92. Branine N. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus. 2026.

    case reporthumann = 1View source

  93. OZEMPIC (oral semaglutide) tablet / RYBELSUS (oral semaglutide) tablet. Prescribing Information, revised 1/2026, DailyMed. U.S. National Library of Medicine, DailyMed. 2026.

    guidancen aView source

  94. OZEMPIC (semaglutide) injection, for subcutaneous use. Prescribing Information, revised 05/2026 (NDA 209637, S-038). U.S. Food and Drug Administration, Drugs@FDA. 2026.

    guidancen aView source

  95. OZEMPIC (semaglutide) injection, solution. Prescribing Information, revised 5/2026, DailyMed. U.S. National Library of Medicine, DailyMed. 2026.

    guidancen aView source

  96. Ozempic: EPAR, Product Information (Annex I, Summary of Product Characteristics). European Medicines Agency. 2026.

    guidancen aView source

  97. Crossan SS, Watkins S. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight Alert. 2026.

    narrative reviewn aView source

  98. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. Federal Register (Food and Drug Administration). 2026.

    guidancen aView source

  99. Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients With Genetically Confirmed Barth Syndrome. ClinicalTrials.gov. 2026.

    rcthumann = 48View source

  100. Pre-approval Expanded Access of Retatrutide (LY3437943). ClinicalTrials.gov. 2026.

    guidancen aView source

  101. Forbes Kaprive J, Merheb E. Protein Structure and Function (StatPearls, NBK562260). StatPearls Publishing, NCBI Bookshelf. 2026.

    narrative reviewn aView source

  102. PubChem Compound CID 146675088 (MOTS-c). PubChem. 2026.

    in silicon aView source

  103. PubChem Compound Summary for CID 129010512, Dihexa. PubChem, National Library of Medicine. 2026.

    in silicon aView source

  104. PubChem Compound Summary for CID 219042, Epitalon. National Center for Biotechnology Information. 2026.

    guidancen aView source

  105. PubChem Compound Summary for CID 68816, Emideltide. National Center for Biotechnology Information. 2026.

    guidancen aView source

  106. PubChem Compound Summary: Afamelanotide (CID 16197727). PubChem. 2026.

    guidancen aView source

  107. PubChem Compound Summary: Elamipretide (CID 11764719). PubChem. 2026.

    guidancen aView source

  108. Heerspink HJL et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrology Dialysis Transplantation. 2026.

    narrative reviewhumann = 146View source

  109. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. 2026.

    rcthumann = 1152View source

  110. Grunstein RR et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. The New England Journal of Medicine. 2026.

    rcthumann = 691View source

  111. Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026.

    rcthumann = 2339View source

  112. RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, for oral use. Prescribing Information, revised 1/2026 (NDA 213051, S-030). U.S. Food and Drug Administration, Drugs@FDA. 2026.

    guidancen aView source

  113. Rybelsus: EPAR, Product Information (Annex I, Summary of Product Characteristics). European Medicines Agency. 2026.

    guidancen aView source

  114. SCENESSE (afamelanotide) implant prescribing information, NDA 210797. U.S. Food and Drug Administration (openFDA drug label). 2026.

    guidancen aView source

  115. Scenesse (afamelanotide): EPAR overview page. European Medicines Agency. 2026.

    guidancen aView source

  116. Selank, PubChem Compound CID 11765600. PubChem, National Library of Medicine. 2026.

    guidancen aView source

  117. Sehgal NKR et al. Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide. JAMA Network Open. 2026.

    self reporthumann = 13589View source

  118. Abdelaal A et al. Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.. Ophthalmology. 2026.

    systematic reviewhumanView source

  119. Khani E et al. Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.. Journal of Clinical Pharmacology. 2026.

    systematic reviewhumanView source

  120. Semax, PubChem Compound CID 9811102. PubChem, National Library of Medicine. 2026.

    guidancen aView source

  121. Stealth BioTherapeutics to Present Updates on Elamipretide in Barth Syndrome and POLG Disease at Euromit 2026. Stealth BioTherapeutics (press release, PR Newswire). 2026.

    press releasen aView source

  122. TGA tests counterfeit retatrutide product following serious adverse event report. Therapeutic Goods Administration. 2026.

    guidancen aView source

  123. The Prohibited List, World Anti-Doping Agency. World Anti-Doping Agency. 2026.

    guidancen aView source

  124. Think twice before injecting peptides bought online: unauthorized products can seriously harm your health. Health Canada (Recalls and safety alerts). 2026.

    guidancen aView source

  125. Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicines. Medicines and Healthcare products Regulatory Agency. 2026.

    guidancen aView source

  126. UniProtKB A0A0C5B5G6 (MOTSC_HUMAN): Mitochondrial-derived peptide MOTS-c. UniProt. 2026.

    in silicon aView source

  127. Vedtak om palegg om stans av ulovlig reklame for melanotan og retatutrid (case 25/34799-15). Direktoratet for medisinske produkter (Norway). 2026.

    guidancen aView source

  128. VYLEESI (bremelanotide injection) prescribing information. U.S. Food and Drug Administration (openFDA drug label). 2026.

    guidancen aView source

  129. WEGOVY (semaglutide) injection and tablets. Prescribing Information, revised 06/2026 (NDA 215256 and NDA 218316). U.S. Food and Drug Administration, Drugs@FDA. 2026.

    guidancen aView source

  130. Wegovy: EPAR, Product Information (Annex I, Summary of Product Characteristics). European Medicines Agency. 2026.

    guidancen aView source

  131. ZEPBOUND (tirzepatide) injection, for subcutaneous use. Prescribing Information, revised 08/2026 (NDA 217806, S-041). U.S. Food and Drug Administration, Drugs@FDA. 2026.

    guidancen aView source

  132. Pokrywka A et al. "Brain doping" substances: prohibited or not in sports?. Biology of Sport. 2025.

    narrative reviewn aView source

  133. A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy Participants. ClinicalTrials.gov. 2025.

    cohorthumann = 43View source

  134. A Phase 1, Open-label, Single-arm Study to Investigate the Effect of Retatrutide on Metoprolol Pharmacokinetics in Healthy Participants. ClinicalTrials.gov. 2025.

    cohorthumann = 30View source

  135. A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes. ClinicalTrials.gov. 2025.

    rcthumann = 146View source

  136. A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower. ClinicalTrials.gov. 2025.

    rcthumann = 102View source

  137. A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction. ClinicalTrials.gov. 2025.

    rcthumann = 85View source

  138. Kanu C et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes, Obesity and Metabolism. 2025.

    rcthumann = 275View source

  139. Application 022505 supplement approval letter, Egrifta WR new formulation, March 25, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  140. Kanu C et al. Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight. Diabetes, Obesity and Metabolism. 2025.

    cohorthumanView source

  141. Chou CC et al. Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Study.. Ophthalmology. 2025.

    cohorthumanView source

  142. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, updated March 21, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  143. Nicholls SJ et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.. The New England Journal of Medicine. 2025.

    rcthumann = 13299View source

  144. Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy), February 21, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  145. Drugs@FDA: FORZINITY (elamipretide hydrochloride), NDA 215244. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  146. Coskun T et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology. 2025.

    rcthumann = 189View source

  147. Ellis RJ et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.. The Journal of Infectious Diseases. 2025.

    rcthumann = 73View source

  148. Sinha B, Ghosal S. Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity. 2025.

    meta analysishumann = 29506View source

  149. Moiz A et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials. Annals of Internal Medicine. 2025.

    systematic reviewhumann = 15491View source

  150. Misra S, Narayan RK, Kaur M. Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. Journal of Basic and Clinical Physiology and Pharmacology. 2025.

    systematic reviewhumann = 691View source

  151. Pallavi K et al. Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis. Maedica. 2025.

    meta analysishumanView source

  152. Abdrabou Abouelmagd A et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proceedings (Baylor University Medical Center). 2025.

    meta analysishumann = 878View source

  153. Hannon TS et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.. The Lancet. 2025.

    rcthumann = 99View source

  154. Tewari J et al. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology. 2025.

    meta analysishumanView source

  155. EGRIFTA WR (tesamorelin) for injection. Prescribing Information, revised 3/2025 (application 022505). U.S. Food and Drug Administration, Drugs@FDA. 2025.

    guidancen aView source

  156. Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.

    systematic reviewother animalView source

  157. Kuceki G et al. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. JAAD International. 2025.

    case serieshumann = 7View source

  158. Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025.

    in vitrocell lineView source

  159. FDA Grants Accelerated Approval for First Treatment for Barth Syndrome. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  160. FDA Warning Letter, MARCS-CMS 696885, February 26, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  161. FDA Warning Letter, MARCS-CMS 712126, September 9, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  162. FDA Warning Letter, MARCS-CMS 713650, September 9, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  163. FDA Warning Letter, MARCS-CMS 715506, September 9, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  164. FDA Warning Letter, MARCS-CMS 715798, September 9, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  165. FDA Warning Letter, MARCS-CMS 715883, September 9, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  166. FDA Warning Letter, MARCS-CMS 716152, December 8, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  167. FDA Warning Letter, MARCS-CMS 716459, September 9, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  168. FORZINITY (elamipretide) injection, prescribing information (Revised 9/2025). DailyMed, U.S. National Library of Medicine (FDA-approved labeling). 2025.

    guidancen aView source

  169. Martino KA et al. Hepatocyte Growth Factor/MET Activator Rescues Working Memory Deficits after Repeated Mild Traumatic Brain Injury. Neurotrauma Reports. 2025.

    animalratn = 52View source

  170. Import Alerts. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  171. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry (January 2025). U.S. Food and Drug Administration. 2025.

    guidancen aView source

  172. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Eli Lilly and Company (press release, PR Newswire). 2025.

    press releasen aView source

  173. Yassin Alsabbagh A, Bhujel N, Singh RP. Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?. International Journal of Oral and Maxillofacial Surgery. 2025.

    case reporthumann = 1View source

  174. MHRA smashes major illicit weight loss medicine production facility in record seizure. Medicines and Healthcare products Regulatory Agency. 2025.

    guidancen aView source

  175. Jozwiak M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals. 2025.

    narrative reviewn aView source

  176. NDA 209637/S-025 supplement approval letter, Ozempic kidney indication, January 28, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  177. NDA 215256/S-024 supplement approval letter, Wegovy MASH indication (accelerated approval), August 15, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  178. NDA 215866/S-039 supplement approval letter, Mounjaro (tirzepatide), pediatric patients 10 years and older with type 2 diabetes, December 19, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  179. NDA 218316 approval letter, Wegovy (semaglutide) tablets, December 22, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  180. Open-Label, Single-Arm Phase 2a Pilot Study to Evaluate the Safety and Tolerability of a Daily Subcutaneous Dose of Elamipretide in Older Adults. ClinicalTrials.gov. 2025.

    case serieshumann = 30View source

  181. McGuire DK et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.. The New England Journal of Medicine. 2025.

    rcthumann = 9650View source

  182. Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.. The New England Journal of Medicine. 2025.

    rcthumanView source

  183. Araj SK et al. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. 2025.

    narrative reviewn aView source

  184. Goetz IA et al. Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. Obesity Pillars. 2025.

    case serieshumann = 40View source

  185. Pharmacy Compounding Advisory Committee, December 4, 2024: Final Summary Minutes. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  186. Sanyal AJ et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.. The New England Journal of Medicine. 2025.

    rcthumanView source

  187. Ehlers JP et al. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmology Science. 2025.

    rcthumann = 176View source

  188. Retraction notice to "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System" [J Pharmacol Exp Ther 351 (2014) 390-402]. The Journal of Pharmacology and Experimental Therapeutics. 2025.

    guidancen aView source

  189. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025.

    case reporthumann = 2View source

  190. Stealth BioTherapeutics Announces "Path Forward" Despite Disappointing Delay for Ultra-rare Barth Syndrome. Stealth BioTherapeutics (press release, PR Newswire). 2025.

    press releasen aView source

  191. Heerspink HJL et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney International Reports. 2025.

    cohorthumann = 619View source

  192. Mitchell W et al. The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell. 2025.

    animalmouseView source

  193. Vanhee C et al. The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories. Journal of Xenobiotics. 2025.

    in vitron aView source

  194. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.. The New England Journal of Medicine. 2025.

    rcthumann = 751View source

  195. Packer M et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.. The New England Journal of Medicine. 2025.

    rcthumann = 731View source

  196. Tolletaten advarer mot Barbie-dop og slankemidler. Tolletaten (Norwegian Customs). 2025.

    guidancen aView source

  197. Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks. Health Canada (Recalls and safety alerts). 2025.

    guidancen aView source

  198. Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks. Health Canada (Recalls and safety alerts). 2025.

    guidancen aView source

  199. Simonsen E et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study.. Diabetes, Obesity and Metabolism. 2025.

    cohorthumanView source

  200. A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants. ClinicalTrials.gov. 2024.

    cohorthumann = 46View source

  201. A Relative Bioavailability Study to Compare the Pharmacokinetics of LY3437943 Administered Subcutaneously by a Test Device (Test Formulation) Versus Reference Device (Reference Formulation) in Healthy Participants. ClinicalTrials.gov. 2024.

    rcthumann = 57View source

  202. Ineichen BV et al. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLoS Biology. 2024.

    systematic reviewn aView source

  203. Higgins JPT et al. Chapter 8: Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions, version 6.5. Cochrane. 2024.

    guidancen aView source

  204. Close to 900,000 units of illegal medicines detained by the HPRA in 2023. Health Products Regulatory Authority (Ireland). 2024.

    guidancen aView source

  205. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.. JAMA. 2024.

    rcthumann = 670View source

  206. Emser SV et al. Corrigendum: Extension of mitogenome enrichment based on single long-range PCR: mtDNAs and putative mitochondrial-derived peptides of five rodent hibernators. Frontiers in Genetics. 2024.

    narrative reviewn aView source

  207. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound), December 19, 2024. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  208. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024.

    case serieshumann = 12View source

  209. Effect of Injection Site on the Relative Bioavailability of a Single Dose of LY3437943 in Healthy Participants With a High Body Mass Index. ClinicalTrials.gov. 2024.

    rcthumann = 85View source

  210. Wells RG et al. Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats. Journal of Huntington's Disease. 2024.

    animalratn = 40View source

  211. Pasqualotto E et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism Open. 2024.

    meta analysishumann = 640View source

  212. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.. The New England Journal of Medicine. 2024.

    rcthumann = 3533View source

  213. EGRIFTA SV (tesamorelin) for injection. Prescribing Information, revised 02/2024 (application 022505). U.S. Food and Drug Administration, Drugs@FDA. 2024.

    guidancen aView source

  214. Karanjia R, Sadun AA. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial. Ophthalmology. 2024.

    rcthumann = 12View source

  215. FDA Briefing Document, Pharmacy Compounding Advisory Committee, December 4, 2024: CJC-1295-Related Bulk Drug Substances. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  216. FDA Briefing Document, Pharmacy Compounding Advisory Committee, October 29, 2024: Ipamorelin-Related Bulk Drug Substances (Ipamorelin (free base) and Ipamorelin Acetate). U.S. Food and Drug Administration. 2024.

    guidancen aView source

  217. FDA Roundup: December 17, 2024. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  218. FDA Warning Letter, MARCS-CMS 694608, December 10, 2024. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  219. FDA Warning Letter, MARCS-CMS 695156, December 10, 2024. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  220. FDA Warning Letter, MARCS-CMS 695607, December 10, 2024. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  221. FDA Warning Letter, MARCS-CMS 695663, December 10, 2024. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  222. FOI 24/274: Side effects reports of melanotan II products. Medicines and Healthcare products Regulatory Agency. 2024.

    guidancen aView source

  223. Human Drug Compounding Laws. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  224. Thompson WR et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine. 2024.

    case serieshumann = 10View source

  225. Ashraf AR et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research. 2024.

    in vitron an = 3View source

  226. NDA 210797/S-007 supplement approval letter, Scenesse (afamelanotide). U.S. Food and Drug Administration. 2024.

    guidancen aView source

  227. NDA 215256/S-011 supplement approval letter, Wegovy cardiovascular risk reduction indication, March 8, 2024. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  228. NDA 217806 S-013 supplement approval letter, Zepbound (tirzepatide), obstructive sleep apnea indication, December 20, 2024. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  229. Pharmacy Compounding Advisory Committee, October 29, 2024: Final Summary Minutes. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  230. PITOCIN (oxytocin) injection. Prescribing Information (NDA 018261), DailyMed. U.S. National Library of Medicine, DailyMed. 2024.

    guidancen aView source

  231. Hathaway JT et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.. JAMA Ophthalmology. 2024.

    cohorthumanView source

  232. Rahaman KA et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences. 2024.

    animalratView source

  233. Zhou Q et al. The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. 2024.

    case controlhumann = 602View source

  234. Bian Y. The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biology. 2024.

    animalmouseView source

  235. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.. The New England Journal of Medicine. 2024.

    rcthumann = 469View source

  236. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024.

    rcthumann = 98View source

  237. Withdrawal of application to change the marketing authorisation for Scenesse (afamelanotide). European Medicines Agency (EMA/243052/2024, EMEA/H/C/002548/II/0044). 2024.

    guidancen aView source

  238. A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Vitiligo (CUV105). ClinicalTrials.gov. 2023.

    rcthumann = 200View source

  239. A Multiple Dose Escalation Study in Chinese Participants With Overweight BMI or Obesity to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943. ClinicalTrials.gov. 2023.

    rcthumann = 32View source

  240. A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes. ClinicalTrials.gov. 2023.

    cohorthumann = 32View source

  241. A Parallel-group, Phase 1, Open-label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Renal Impairment Compared With Healthy Participants. ClinicalTrials.gov. 2023.

    cohorthumann = 29View source

  242. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Updated September 29, 2023). U.S. Food and Drug Administration (copy hosted by the Alliance for Pharmacy Compounding). 2023.

    guidancen aView source

  243. Disposition of [14C]-LY3437943 Following Subcutaneous Administration in Healthy Male Participants. ClinicalTrials.gov. 2023.

    cohorthumann = 7View source

  244. Karaa A et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023.

    rcthumann = 218View source

  245. HUMULIN R (insulin human) injection, solution. Prescribing Information (BLA 018780), DailyMed. U.S. National Library of Medicine, DailyMed. 2023.

    guidancen aView source

  246. Campbell MD, Samuelson AT, Chiao YA. Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice. GeroScience. 2023.

    animalmouseView source

  247. NDA 217806 approval letter, Zepbound (tirzepatide) injection, November 8, 2023. U.S. Food and Drug Administration. 2023.

    guidancen aView source

  248. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023.

    rcthumann = 281View source

  249. Retraction Watch (Crossref documentation). Crossref. 2023.

    guidancen aView source

  250. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.. The New England Journal of Medicine. 2023.

    rcthumann = 17604View source

  251. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.. The New England Journal of Medicine. 2023.

    rcthumann = 529View source

  252. Delcourt V et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Testing and Analysis. 2023.

    in vitron aView source

  253. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.. The Lancet. 2023.

    rcthumann = 938View source

  254. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. 2023.

    rcthumann = 338View source

  255. Dragon AK et al. [Results of the application of complex physiotherapeutic neurostimulation in optical neuropathies of various genesis]. Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury. 2022.

    case serieshumann = 60View source

  256. A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus. ClinicalTrials.gov. 2022.

    rcthumann = 64View source

  257. Coppieters G et al. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.. Journal of Pharmaceutical and Biomedical Analysis. 2022.

    in vitron aView source

  258. Deigin VI et al. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics. 2022.

    narrative reviewn aView source

  259. EU/3/22/2614: orphan designation for treatment of myopathic mitochondrial DNA depletion syndrome (elamipretide). European Medicines Agency. 2022.

    guidancen aView source

  260. Zhang Q. Glycyl-L-histidyl-L-lysine-Cu(2+) attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Frontiers in Molecular Biosciences. 2022.

    animalmousen = 60View source

  261. Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022.

    rcthumann = 72View source

  262. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022.

    animalmouseView source

  263. NDA 215866 approval letter, Mounjaro (tirzepatide) injection, May 13, 2022. U.S. Food and Drug Administration. 2022.

    guidancen aView source

  264. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity.. The New England Journal of Medicine. 2022.

    rcthumann = 201View source

  265. He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022.

    animalratView source

  266. Hua X et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. Journal of Alzheimer's Disease. 2022.

    rcthumanView source

  267. Wang L et al. Therapeutic peptides: current applications and future directions.. Signal Transduction and Targeted Therapy. 2022.

    narrative reviewn aView source

  268. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity.. The New England Journal of Medicine. 2022.

    rcthumann = 2539View source

  269. A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. ClinicalTrials.gov. 2021.

    rcthumann = 88View source

  270. Reid Thompson W et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine. 2021.

    rcthumann = 12View source

  271. Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021.

    case controlhumann = 27527View source

  272. von Walden F, Alkner B. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Journal of Applied Physiology. 2021.

    case controlhumanView source

  273. Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE) (CUV032). ClinicalTrials.gov. 2021.

    rcthumann = 31View source

  274. Høj LJ et al. Analysis of seized peptide and protein-based doping agents using four complimentary methods: Liquid chromatography coupled with time of flight mass spectrometry, liquid chromatography-ultraviolet, Bradford, and immunoassays. Drug Testing and Analysis. 2021.

    in vitron an = 36View source

  275. Sun X et al. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sciences. 2021.

    animalmouseView source

  276. CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity (Form 8-K Exhibit 99.2). CohBar, Inc., filed with the U.S. Securities and Exchange Commission. 2021.

    press releasehumann = 20View source

  277. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.. JAMA. 2021.

    rcthumann = 803View source

  278. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.. The Lancet. 2021.

    rcthumann = 478View source

  279. FOI 21/1237: Yellow Card reports for melanotan II products, 2011 to 2021. Medicines and Healthcare products Regulatory Agency. 2021.

    guidancen aView source

  280. Roshanravan B et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021.

    rcthumann = 39View source

  281. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021.

    case serieshumann = 17View source

  282. Mestria S et al. LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. Drug Testing and Analysis. 2021.

    in vitron aView source

  283. Mallory CW, Lopategui DM, Cordon BH. Melanotan Tanning Injection: A Rare Cause of Priapism. Sexual Medicine. 2021.

    case reporthumann = 1View source

  284. Kong BS et al. Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell Reports. 2021.

    animalmouseView source

  285. Reynolds JC, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021.

    animalmouseView source

  286. NDA 215256 approval letter, Wegovy (semaglutide) injection, June 4, 2021. U.S. Food and Drug Administration. 2021.

    guidancen aView source

  287. Notice of Concern: McCoy AT, Benoist CC, Wright JW, et al. (2013) Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents. The Journal of Pharmacology and Experimental Therapeutics. 2021.

    guidancen aView source

  288. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England Journal of Medicine. 2021.

    rcthumann = 1961View source

  289. Sequeira IR, Merry TL. Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes. Biochimica et Biophysica Acta General Subjects. 2021.

    case controlhumann = 125View source

  290. Davies M et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.. The Lancet. 2021.

    rcthumann = 1210View source

  291. Weiss JB et al. Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies. Annals of Medicine and Surgery. 2021.

    animalratView source

  292. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.. The New England Journal of Medicine. 2021.

    rcthumann = 1879View source

  293. Muttenthaler M et al. Trends in peptide drug discovery.. Nature Reviews Drug Discovery. 2021.

    narrative reviewn aView source

  294. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of a Single Intravenous Dose of MTP-131 (Bendavia™) on Skeletal Muscle Function in the Elderly. ClinicalTrials.gov. 2020.

    rcthumann = 41View source

  295. Karaa A, Haas R, Goldstein A. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Journal of Cachexia, Sarcopenia and Muscle. 2020.

    rcthumann = 30View source

  296. Ivko OM et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Advances in Gerontology (Uspekhi Gerontologii). 2020.

    case serieshumanView source

  297. Butler J et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. Journal of Cardiac Failure. 2020.

    rcthumann = 71View source

  298. Panikratova YR et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. 2020.

    case serieshumann = 52View source

  299. D'Souza RF, Merry TL. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY). 2020.

    case controlhumanView source

  300. Chiao YA, Zhang H, Sweetwyne M. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife. 2020.

    animalmouseView source

  301. Xu C et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020.

    animalratView source

  302. Ma WH. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sciences. 2020.

    animalmouseView source

  303. Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry. 2019.

    in vitron aView source

  304. Khavinson VK et al. Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes. Bulletin of Experimental Biology and Medicine. 2019.

    in vitrocell lineView source

  305. Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.. The Lancet HIV. 2019.

    rcthumann = 61View source

  306. Gajda PM et al. Glycine-modified growth hormone secretagogues identified in seized doping material.. Drug Testing and Analysis. 2019.

    in vitron aView source

  307. List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act (final rule, 84 FR 4696). Federal Register (Food and Drug Administration). 2019.

    guidancen aView source

  308. Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Reports. 2019.

    case reporthumann = 1View source

  309. Lu H et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. Journal of Molecular Medicine. 2019.

    animalmouseView source

  310. NDA 210797 approval letter, Scenesse (afamelanotide) implant, 16 mg. U.S. Food and Drug Administration. 2019.

    guidancen aView source

  311. NDA 210797 Scenesse (afamelanotide) Multi-disciplinary Review and Evaluation. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 2019.

    guidancen aView source

  312. NDA 213051 approval letter, Rybelsus (semaglutide) tablets, September 20, 2019. U.S. Food and Drug Administration. 2019.

    guidancen aView source

  313. Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.. The New England Journal of Medicine. 2019.

    rcthumann = 3183View source

  314. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.. Diabetes Care. 2019.

    rcthumann = 703View source

  315. Adrian S et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.. The Journal of Frailty & Aging. 2019.

    cohorthumanView source

  316. Gusev EI et al. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018.

    case serieshumann = 110View source

  317. Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. Neuroscience and Biobehavioral Reviews. 2018.

    systematic reviewn aView source

  318. Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®. ClinicalTrials.gov. 2018.

    rcthumann = 129View source

  319. Qin Q, Lerman A. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. International Journal of Cardiology. 2018.

    case controlhumann = 40View source

  320. Lebedeva IS et al. Effects of Semax on the Default Mode Network of the Brain. Bulletin of Experimental Biology and Medicine. 2018.

    case serieshumann = 24View source

  321. Bertin ACJ, Vilarinho A, Junqueira ALA. Fractional non-ablative laser-assisted drug delivery leads to improvement in male and female pattern hair loss. Journal of Cosmetic and Laser Therapy. 2018.

    case serieshumann = 4View source

  322. Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. Journal of Cosmetic and Laser Therapy. 2018.

    case serieshumann = 1000View source

  323. Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®. ClinicalTrials.gov. 2018.

    cohorthumann = 391View source

  324. Cataldo LR, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. Journal of Investigative Medicine. 2018.

    case controlhumann = 20View source

  325. Karaa A, Haas R, Goldstein A. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018.

    rcthumann = 36View source

  326. Surrogate Endpoint Resources for Drug and Biologic Development. U.S. Food and Drug Administration. 2018.

    guidancen aView source

  327. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions.. Bioorganic & Medicinal Chemistry. 2018.

    narrative reviewn aView source

  328. Shah R, Reyes-Gordillo K, Rojkind M. Thymosin beta 4 inhibits PDGF-BB induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain. Expert Opinion on Biological Therapy. 2018.

    in vitrocell lineView source

  329. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.. The Lancet Diabetes & Endocrinology. 2017.

    rcthumann = 388View source

  330. Filatova E et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology. 2017.

    in vitrocell lineView source

  331. Khavinson VKh et al. Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland. Bulletin of Experimental Biology and Medicine. 2017.

    in vitron aView source

  332. Lundh A et al. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews. 2017.

    systematic reviewn aView source

  333. NDA 209637 approval letter, Ozempic (semaglutide) injection, December 5, 2017. U.S. Food and Drug Administration. 2017.

    guidancen aView source

  334. Daubert MA, Yow E, Dunn G. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circulation: Heart Failure. 2017.

    rcthumann = 36View source

  335. Kasian A et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. 2017.

    animalratView source

  336. Habbema L et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology. 2017.

    narrative reviewhumanView source

  337. Kobylyanskii AG et al. Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells. Bulletin of Experimental Biology and Medicine. 2017.

    in vitrocell lineView source

  338. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017.

    in vitrocell lineView source

  339. Edward Manookian (Also Known as Ed Manning): Debarment Order. Federal Register (Food and Drug Administration). 2016.

    guidancen aView source

  340. Lee WJ et al. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Annals of Dermatology. 2016.

    rcthumanView source

  341. Gibson CM et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal. 2016.

    rcthumanView source

  342. Ming W et al. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochemical and Biophysical Research Communications. 2016.

    animalmouseView source

  343. Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016.

    animalratView source

  344. Li H et al. Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds. Scientific Reports. 2016.

    in vitrocell lineView source

  345. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.. The New England Journal of Medicine. 2016.

    rcthumann = 3297View source

  346. Medvedev VE et al. [Optimization of the treatment of anxiety disorders with selank]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015.

    case serieshumann = 70View source

  347. Lim HW et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatology. 2015.

    rcthumann = 55View source

  348. Langendonk JG et al. Afamelanotide for Erythropoietic Protoporphyria. The New England Journal of Medicine. 2015.

    rcthumann = 168View source

  349. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015.

    narrative reviewn aView source

  350. Uribe PM et al. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Frontiers in Cellular Neuroscience. 2015.

    animalother animalView source

  351. Breindahl T et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Testing and Analysis. 2015.

    in vitron aView source

  352. Li H et al. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharmaceutical Research. 2015.

    in vitrohumanView source

  353. Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source. ClinicalTrials.gov. 2015.

    rcthumann = 42View source

  354. Proposal to Debar; Notice of Opportunity for Hearing, Docket No. FDA-2015-N-4169 (Edward Manookian, Melanocorp). U.S. Food and Drug Administration, Office of Enforcement & Import Operations. 2015.

    guidancen aView source

  355. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015.

    animalmouseView source

  356. Fu SC. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. Journal of Orthopaedic Research. 2015.

    animalratn = 72View source

  357. Medvedev VE et al. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2014.

    case serieshumann = 60View source

  358. Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.. JAMA. 2014.

    rcthumann = 50View source

  359. Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events. ClinicalTrials.gov. 2014.

    rcthumann = 300View source

  360. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. BioMed Research International. 2014.

    in silicocell lineView source

  361. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014.

    case reporthumann = 1View source

  362. Chang CH et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014.

    in vitroratView source

  363. Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.. International Journal of Colorectal Disease. 2014.

    rcthumann = 114View source

  364. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. ClinicalTrials.gov. 2014.

    rcthumann = 320View source

  365. Medvedeva EV et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014.

    animalratView source

  366. Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system (RETRACTED). The Journal of Pharmacology and Experimental Therapeutics. 2014.

    animalratView source

  367. Kolomin T et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Molecular Immunology. 2014.

    animalmouseView source

  368. Nazarova GA et al. [The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy]. Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury. 2013.

    case serieshumann = 114View source

  369. McCoy AT et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. The Journal of Pharmacology and Experimental Therapeutics. 2013.

    animalratView source

  370. Button KS et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience. 2013.

    narrative reviewn aView source

  371. Campbell JD et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine. 2012.

    in vitrocell lineView source

  372. Sivyer GW. Changes of melanocytic lesions induced by Melanotan injections and sun bed use in a teenage patient with FAMMM syndrome. Dermatology Practical & Conceptual. 2012.

    case reporthumann = 1View source

  373. Ho ENM et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta 4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A. 2012.

    animalother animalView source

  374. Baker LD et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.. Archives of Neurology. 2012.

    rcthumann = 152View source

  375. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology. 2012.

    case reporthumann = 1View source

  376. Makimura H et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.. The Journal of Clinical Endocrinology & Metabolism. 2012.

    rcthumann = 60View source

  377. Fang FC, Steen RG, Casadevall A. Misconduct accounts for the majority of retracted scientific publications. Proceedings of the National Academy of Sciences of the United States of America. 2012.

    systematic reviewn aView source

  378. Prospective Alzheimers drug builds new brain cell connections. Washington State University News. 2012.

    press releasen aView source

  379. Questions and answers: Withdrawal of the marketing authorisation application for Egrifta (tesamorelin), 12 July 2012 (EMA/CHMP/475021/2012). European Medicines Agency. 2012.

    guidancen aView source

  380. Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012.

    in vitron aView source

  381. Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting. ClinicalTrials.gov. 2011.

    rcthumann = 3View source

  382. Kolomin T et al. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regulatory Peptides. 2011.

    animalmouseView source

  383. Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research. 2011.

    in vitrohumanView source

  384. Mikhaleva II et al. JmjC-domain-containing histone demethylases of the JMJD1B type as putative precursors of endogenous DSIP. Peptides. 2011.

    in silicon aView source

  385. Korkushko OV et al. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bulletin of Experimental Biology and Medicine. 2011.

    rcthumann = 79View source

  386. Haylett AK et al. Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH. British Journal of Dermatology. 2011.

    case serieshumann = 5View source

  387. Stavchansky VV et al. The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. Journal of Molecular Neuroscience. 2011.

    animalratView source

  388. Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011.

    in vitroratView source

  389. Warning against the tanning product Melanotan. Danish Medicines Agency (Lægemiddelstyrelsen). 2011.

    guidancen aView source

  390. Sosne G et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal. 2010.

    narrative reviewn aView source

  391. Schulz KF et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010.

    guidancen aView source

  392. Falutz J et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.. Journal of Acquired Immune Deficiency Syndromes. 2010.

    rcthumann = 404View source

  393. Hostynek JJ, Dreher F, Maibach HI. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflammation Research. 2010.

    in vitrohumanView source

  394. Henninge J et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.. Drug Testing and Analysis. 2010.

    in vitron aView source

  395. NDA 022505 approval letter, Egrifta (tesamorelin for injection), November 10, 2010. U.S. Food and Drug Administration. 2010.

    guidancen aView source

  396. Cerovecki T et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010.

    animalratView source

  397. Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP) (CUV030). ClinicalTrials.gov. 2010.

    rcthumann = 77View source

  398. Boutron I et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA. 2010.

    systematic reviewn aView source

  399. Search Orphan Drug Designations and Approvals: Epitalon, treatment of retinitis pigmentosa. U.S. Food and Drug Administration. 2010.

    guidancen aView source

  400. Ershov FI et al. [Antiviral activity of immunomodulator Selank in experimental influenza infection]. Voprosy virusologii. 2009.

    animalmouseView source

  401. Cardones AR, Grichnik JM. alpha-Melanocyte-stimulating hormone-induced eruptive nevi. Archives of Dermatology. 2009.

    case reporthumann = 1View source

  402. Pomfrett CJ et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. European Journal of Anaesthesiology. 2009.

    rcthumann = 24View source

  403. Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.. The Journal of Pharmacology and Experimental Therapeutics. 2009.

    animalratView source

  404. Zozulia AA et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2008.

    case serieshumann = 62View source

  405. Uchakina ON et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2008.

    case serieshumanView source

  406. Novinscak T et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surgery Today. 2008.

    animalratView source

  407. Vinogradova IA et al. Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens. Bulletin of Experimental Biology and Medicine. 2008.

    animalratView source

  408. Falutz J et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.. AIDS. 2008.

    rcthumanView source

  409. Warning against the product Melanotan. Danish Medicines Agency (Laegemiddelstyrelsen). 2008.

    guidancen aView source

  410. Serdiuk AV et al. [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2007.

    case serieshumann = 27View source

  411. Vinogradova IA et al. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bulletin of Experimental Biology and Medicine. 2007.

    animalratView source

  412. King SH et al. Melanocortin receptors, melanotropic peptides and penile erection. Current Topics in Medicinal Chemistry. 2007.

    narrative reviewn aView source

  413. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England Journal of Medicine. 2007.

    rcthumann = 412View source

  414. Agapova TY et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neuroscience Letters. 2007.

    animalratView source

  415. Korkushko OV et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Advances in Gerontology (Uspekhi Gerontologii). 2007.

    case serieshumanView source

  416. Pyo HK et al. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007.

    in vitrocell lineView source

  417. Barnetson RS et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. Journal of Investigative Dermatology. 2006.

    rcthumann = 65View source

  418. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. ClinicalTrials.gov. 2006.

    rcthumann = 120View source

  419. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006.

    narrative reviewn aView source

  420. Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. 2006.

    rcthumann = 13View source

  421. Cangul IT et al. Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Veterinary Dermatology. 2006.

    animalother animaln = 18View source

  422. Korkushko OV et al. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bulletin of Experimental Biology and Medicine. 2006.

    rcthumanView source

  423. Romanova GA et al. Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex. Bulletin of Experimental Biology and Medicine. 2006.

    animalratView source

  424. Alba M et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.. American Journal of Physiology. Endocrinology and Metabolism. 2006.

    animalmouseView source

  425. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of Clinical Endocrinology & Metabolism. 2006.

    rcthumanView source

  426. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.. The Journal of Clinical Endocrinology & Metabolism. 2006.

    case serieshumanView source

  427. Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006.

    animalratView source

  428. Gusev EI, Skvortsova VI, Chukanova EI. [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2005.

    case serieshumann = 187View source

  429. Anisimov VN et al. Effect of epitalon and melatonin on life span and spontaneous carcinogenesis in senescence accelerated mice (SAM). Voprosy Onkologii. 2005.

    animalmouseView source

  430. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.. Endocrinology. 2005.

    animalratView source

  431. Eremin KO et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research. 2005.

    animalmouseView source

  432. Khavinson VKh et al. Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine. 2004.

    in vitrocell lineView source

  433. Semenchenko GV, Anisimov VN, Yashin AI. Stressors and antistressors: how do they influence life span in HER-2/neu transgenic mice?. Experimental Gerontology. 2004.

    animalmouseView source

  434. Popovich IG et al. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mechanisms of Ageing and Development. 2003.

    animalmouseView source

  435. Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003.

    animalmouseView source

  436. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003.

    in vitrocell lineView source

  437. Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003.

    animalratView source

  438. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. 2003.

    cohorthumann = 266View source

  439. Kozlovskaya MM et al. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neuroscience and Behavioral Physiology. 2003.

    animalratView source

  440. Porst H. Therapy of erectile dysfunction in 2005. Der Urologe Ausgabe A. 2003.

    narrative reviewn aView source

  441. Philp D et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration. 2003.

    animalmouseView source

  442. Anisimov VN et al. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. Bulletin of Experimental Biology and Medicine. 2002.

    animalmouseView source

  443. Anisimov VN et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International Journal of Cancer. 2002.

    animalmouseView source

  444. Khavinson V et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters. 2002.

    case serieshumanView source

  445. Ivanikov IO et al. Therapy of peptic ulcer with semax peptide. Bulletin of Experimental Biology and Medicine. 2002.

    case serieshumanView source

  446. Kost NV et al. [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]. Bioorganicheskaia khimiia. 2001.

    in vitron aView source

  447. Kurysheva NI et al. [Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone]. Vestnik oftalmologii. 2001.

    case serieshumanView source

  448. Lall S et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.. Biochemical and Biophysical Research Communications. 2001.

    animalmouseView source

  449. Andersen NB et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.. Growth Hormone & IGF Research. 2001.

    animalratView source

  450. Zozulya AA et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001.

    in vitron aView source

  451. Polunin GS et al. [Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]. Vestnik oftalmologii. 2000.

    case serieshumanView source

  452. Wessells H et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000.

    case serieshumann = 10View source

  453. Khavinson VK et al. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development. 2000.

    animalother animalView source

  454. Wessells H et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research. 2000.

    narrative reviewhumanView source

  455. Miasoedova NF et al. [Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 1999.

    case serieshumanView source

  456. Alekseeva GV, Bottaev NA, Goroshkova VV. [Use of semax at a follow-up of patients with posthypoxic encephalopathy]. Anesteziologiia i reanimatologiia. 1999.

    case serieshumann = 73View source

  457. Johansen PB et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.. Growth Hormone & IGF Research. 1999.

    animalratView source

  458. Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.. Pharmaceutical Research. 1999.

    case serieshumanView source

  459. Abdulghani AA et al. Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin: a pilot clinical, histologic, and ultrastructural study. Disease Management and Clinical Outcomes. 1998.

    case serieshumann = 20View source

  460. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue.. European Journal of Endocrinology. 1998.

    animalother animalView source

  461. Wessells H et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. The Journal of Urology. 1998.

    case serieshumann = 10View source

  462. Asmarin IP et al. [A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study)]. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova. 1997.

    narrative reviewhumanView source

  463. Gusev EI et al. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 1997.

    case serieshumann = 110View source

  464. Fan W et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997.

    animalmouseView source

  465. Endo T, Miyagi M, Ujiie A. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. Journal of Chromatography B, Biomedical Sciences and Applications. 1997.

    animalratView source

  466. Swaim SF et al. Effect of locally injected medications on healing of pad wounds in dogs. American Journal of Veterinary Research. 1996.

    animalother animaln = 12View source

  467. Dorr RT et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996.

    case serieshumann = 3View source

  468. Späth-Schwalbe E et al. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology. 1995.

    case serieshumanView source

  469. Chiodera P et al. Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men. Hormone Research. 1994.

    case serieshumann = 8View source

  470. Mulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair and Regeneration. 1994.

    rcthumanView source

  471. Uno H, Kurata S. Chemical agents and peptides affect hair growth. The Journal of Investigative Dermatology. 1993.

    narrative reviewn aView source

  472. Potaman VN et al. Degradation of ACTH/MSH(4-10) and its synthetic analog semax by rat serum enzymes: an inhibitor study. Peptides. 1993.

    in vitroratView source

  473. Giusti M et al. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology. 1993.

    case serieshumann = 8View source

  474. Maquart FX et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. The Journal of Clinical Investigation. 1993.

    animalratView source

  475. Bishop JB et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of Vascular Surgery. 1992.

    rcthumann = 86View source

  476. Bes F et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992.

    case serieshumann = 16View source

  477. Potaman VN et al. N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat blood enzymes. Biochemical and Biophysical Research Communications. 1991.

    in vitroratView source

  478. Bjartell A et al. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology. 1989.

    rcthumann = 11View source

  479. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. European Neurology. 1987.

    case serieshumann = 14View source

  480. Monti JM et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research. 1987.

    case serieshumanView source

  481. Sušić V, Masirević G, Totić S. The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat. Brain Research. 1987.

    animalother animaln = 10View source

  482. Schneider-Helmert D. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. European Neurology. 1986.

    case serieshumann = 18View source

  483. Obál F Jr et al. Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep. Pharmacology Biochemistry and Behavior. 1986.

    animalratView source

  484. Obál F Jr et al. Effects of intracerebroventricular injection of delta sleep-inducing peptide (DSIP) and an analogue on sleep and brain temperature in rats at night. Pharmacology Biochemistry and Behavior. 1985.

    animalratView source

  485. Sommerfelt L. Reduced sleep in cats after intraperitoneal injection of delta-sleep-inducing peptide (DSIP). Neuroscience Letters. 1985.

    animalother animalView source

  486. Kaeser HE. A clinical trial with DSIP. European Neurology. 1984.

    case serieshumann = 7View source

  487. Dick P et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. European Neurology. 1984.

    case serieshumann = 107View source

  488. Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology. 1983.

    case serieshumann = 67View source

  489. Schneider-Helmert D. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. International Journal of Clinical Pharmacology, Therapy, and Toxicology. 1981.

    case serieshumann = 6View source

  490. Schneider-Helmert D. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981.

    case serieshumann = 6View source

  491. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences of the USA. 1977.

    animalother animaln = 58View source